



The Global Roundtable Series

October 2012 - Geneva, Switzerland

Assuring Balance for Non-communicable Diseases

In September of this year, the global health community proudly celebrated the one year anniversary of the United Nations (UN) High-level Meeting on Non-communicable Diseases (NCDs), held 19-20 September 2011, and the adoption of the UN Political Declaration on NCDs. This past year has seen tremendous progress on NCDs at the global level, most notably with the adoption of a global target to reduce premature deaths from NCDs by 25% by 2025 (known as "25 by 25") at the World Health Assembly in May 2012. The World Health Organization (WHO) has also led a series of consultations that are vitally important to global action on NCDs.

These consultations will result in:

1. A Global Monitoring Framework, with indicators, and a set of voluntary global targets for the prevention and control of NCDs
2. Options for strengthening and facilitating multisectoral action for the prevention and control of NCDs through partnerships
3. A 'Global Action Plan for the Prevention and Control of NCDs 2013–2020'

Building on advocacy efforts initiated last year to deliver a set of meaningful targets and indicators that reflect the full continuum of cancer care, from prevention, early detection, treatment, to care and palliation, UICC, in collaboration with the United States Mission and Panama Mission to the UN in Geneva, arranged a roundtable discussion. This was a uniquely global and multisectoral event with representatives from over 20 UN Missions, as well as representatives from the WHO, other UN agencies, non-governmental organisations, and the private sector.

During this 90-minute discussion, participants had the opportunity to share views on the emerging Global NCD Framework, with particular focus on the Global Monitoring Framework that would be finalised by Member States at a formal consultation the week of 5 November 2012. There was strong consensus around the table that the Global Monitoring Framework should embrace NCD targets and indicators beyond prevention, and recognise that we have a responsibility to the millions of individuals worldwide already living with NCDs.





“We need to have balance between prevention and care, we must not forget those who are already ill.”

Dr Oleg Chestnov, Assistant-Director General of NCDs and Mental Health, WHO



“A Global Monitoring Framework is necessary to follow the evolution of NCDs and will help governments develop political, financial and legal measures, as well as implement programmes.”

Deputy Ambassador Jessie Solano De Marach, Panama Mission to the UN

“We need to look to WHO best buys and examine explicit examples of feasible and affordable treatments in the countries regardless of the setting, as this can have a large impact in low- and middle-income countries.”

Chris Gray, Senior Director of International Public Affairs, Pfizer Inc.

Key Advocacy Messages

Achievement of the goal to reduce premature NCD deaths by 25% by 2025 requires:

1. Recognition that NCDs require a multisectoral response involving whole-of-government, UN agencies, civil society and private sector
2. Recognition that NCDs are more than just a health issue; the priorities and targets of the NCD framework must be fully integrated into the next generation of development goals – the Post 2015 Development Framework
3. Full integration of the Global Monitoring Framework with other complimentary components of the global NCD framework – the ‘Global Action Plan for the Prevention and Control of NCDs 2013-2020’, and Global Coordinating Mechanism for NCDs
4. A Global Monitoring Framework for NCDs that:
 - Delivers a comprehensive set of bold targets and indicators to drive progress towards “25 by 2025”
 - Strikes a balance between targets on prevention with those of detection, diagnosis, treatment and care for NCDs
 - Supports the application of global targets to regional and national levels
 - Includes a rigorous reporting system
 - Recognises the need to build the technical capacity of Member States to measure indicators.

“The U.S. fully endorses the global target to reduce premature deaths from NCDs by 25% by 2025, adopted by World Health Assembly in May 2012. The remaining targets should be measurable and achievable and monitored with technically sound indicators; and should be evidence based... civil society, government and private sector must work together.”

Her Excellency Ms Betty King, U.S. Ambassador to the United Nations in Geneva

Speakers

- **Mr Cary Adams**, Chief Executive Officer, Union for International Cancer Control (Moderator)
- **Her Excellency Ms Betty King**, U.S. Ambassador to the United Nations in Geneva, Permanent Mission of the United States of America to the United Nations
- **Her Excellency Mrs Jessie Solano De Marach** Deputy Ambassador, Permanent Mission of Panama to the United Nations
- **Dr Oleg Chestnov**, Assistant Director-General, Noncommunicable Diseases and Mental Health, World Health Organization
- **Dr John Seffrin**, Chief Executive Officer, American Cancer Society*
- **Mr Michel Rudophie**, President and Chief Executive Officer, Dutch Cancer Society*
- **Mr Peter F. Mulrean**, Deputy Permanent Representative to the United Nations in Geneva, Permanent Mission of the United States of America to the United Nations

Global Impact

Recognising the level of commitment and expertise around the table during this event, and noting UICC's concern about civil society's exclusion from the formal Member State consultation on the Global Monitoring Framework for NCDs scheduled to take place from 5-7 November, the US delegation and Norwegian Chair proposed that NGOs, including UICC, be permitted to participate as observers. As a result, UICC, NCD Alliance partners and other civil society groups were able to follow these critical discussions in the main hall of the WHO, and were given the opportunity to deliver a statement.

Cary Adams, CEO of UICC and Chair of the NCD Alliance made an impassioned plea to Member States to support targets on all four major risk factors, as well as health systems targets on drug therapy and the availability of essential NCD medicines and technologies. He concluded by reassuring Member States that civil society stand ready to help them address NCDs.

The approved set of nine global targets and 25 indicators is a milestone achievement and sends the strong message that all countries are committed to achieve their ambition to reduce premature deaths from NCDs by 25% by 2025.

The global targets cover prevention (tobacco, physical inactivity, alcohol salt, raised blood pressure, and diabetes/obesity) and the health system response (improving the availability of essential medicines and technologies, and counselling and drug therapy for the prevention of heart attack and stroke). The official WHO report on the NCD targets and indicators is available on the WHO website.

UICC welcomes in particular the adoption of indicators on access to palliative care, HPV and HBV vaccination, and cervical cancer screening.

Over the coming months, UICC and NCD Alliance partners will continue advocacy efforts to ensure that key issues not addressed in the Global Monitoring Framework, will be not be lost, but rather integrated into the Global Action Plan for NCDs 2013-2020, in particular screening for breast cancer.



“In the SEARO (South-East Asia Regional Office) region, it is agreed that the number [25% by 2025] is too ambitious...we need to note that efforts for curbing NCD issues for some countries have just started, but it doesn't mean we should stop our efforts to catch up.”

Rolliansyah Soemirat, First Secretary, Republic of Indonesia Mission to the UN

“We are partnering with UICC on international work with commitment to global capacity building...Our message is that UICC members, as well as our partners in the NCD Alliance are willing to align these civil society efforts in a global partnership for NCDs – working across all sectors.”

Michel Rudolphie, CEO, Dutch Cancer Society



“We are at an unprecedented place with an extraordinary opportunity to save lives... targets and indicators must be sure to cover the continuum of the NCD process – from primary prevention to treatment and palliative care.”

Dr John Seffrin, CEO, American Cancer Society

“There is a lot of consensus on need to address the full continuum of NCDs and the need for a comprehensive pan-UN multi-stakeholder approach. All of this is going to be hard, but it is achievable. We cannot miss this opportunity.”

Peter F. Mulrean, Deputy Permanent Representative, United States Mission to the UN

* The Global Roundtable Series has been made possible through 'Together We are Stronger', a UICC-led campaign benefitting the global cancer community. We would like to give special thanks to our Vanguard Champions for their support and commitment.

List of Participants

Organised by Affiliation

- **Mr Raul Pelaez**, Minister, Permanent Mission of the Argentine Republic to the United Nations
- **Ms Cath Patterson**, Minister Counsellor - Health, Permanent Mission of Australia to the United Nations
- **Mr Bruno Henrique Neves Silva**, Second Secretary, Permanent Mission of Brazil to the United Nations
- **Ms Alison LeClaire Christie**, Deputy Permanent Representative, Permanent Mission of Canada to the United Nations
- **Mrs Lulit Zewdie Mariam**, Minister Counsellor, Permanent Mission of the Federal Democratic Republic of Ethiopia to the United Nations
- **Ms Ghadeer El Fayez**, Advisor, Permanent Mission of the Hashemite Kingdom of Jordan to the United Nations
- **Dr Rajesh Ranjan**, First Secretary - Specialised Agencies, Permanent Mission of India to the United Nations
- **Ms Tyesha Turner**, First Secretary, Permanent Mission of Jamaica to the United Nations
- **Mr Roland Driec**, Health Counsellor, Political Department / Health Affairs, Permanent Mission of the Kingdom of the Netherlands
- **Mr Miguel Angel Toscano Velasco**, Minister, Permanent Mission of Mexico to the United Nations
- **His Excellency Mr Umunna Humphrey Orjiako**, Ambassador Extraordinary and Plenipotentiary Permanent Representative, Permanent Mission of the Federal Republic of Nigeria to the United Nations
- **Mr Sverre Berg Lutnæs**, Health Attaché, Permanent Mission of Norway
- **Mr Alexey Kulikov**, Third Secretary (Health Affairs), Permanent Mission of the Russian Federation to the United Nations
- **Mr Grigory Ustinov**, First Secretary, Permanent Mission of the Russian Federation to the United Nations
- **Mr Alphonse Kayitayire**, First Counselor, Permanent Mission of the Republic of Rwanda to the United Nations
- **Mr Rolliansyah Soemirat**, First Secretary the Permanent Mission of the Republic of Indonesia to the United Nations
- **Ms Kris Easter**, Development Advisor, USAID, Permanent Mission of the United States of America to the United Nations
- **Mr Colin McLiff**, Health Attaché, Permanent Mission of the United States of America to the United Nations
- **Her Excellency Ms Encyla Chishiba Tina Sinjela**, Ambassador Extraordinary and Plenipotentiary Permanent Representative, Permanent Mission of the Republic of Zambia to the United Nations
- **Mr Herb Riband**, Vice President of Value, Access & Policy, Amgen

- **Ms Heather Chappell**, Director, Cancer Control Policy, Canadian Cancer Society *
- **Ms Joelle Walker**, Senior Analyst, Public Issues, Canadian Cancer Society *
- **Ms Cora Honing**, International Relations Officer, Dutch Cancer Society *
- **Ms Thea Emmerling**, Minister Counsellor, Health and Food Safety, European Union
- **Dr Marc R. Keller**, Director of Information Department and International Affairs, French Cancer Society
- **Ms Diane Summers**, Senior Specialist in Advocacy and Communication, Global Alliance for Vaccines and Immunisation (GAVI)
- **Ms Eva Gubern**, Commercial Director of Oncology, GlaxoSmithKline *
- **Dr Marion Piñeros-Petersen**, Public Health Consultant, PPO, International Atomic Energy Agency (IAEA)
- **Dr Silvia Franceschi**, Head of the Section of Infections, International Agency for Research on Cancer (IARC)
- **Ms Loyce Pace Bass**, Director of Health Policy, LIVESTRONG Foundation *
- **Dr Vivien Davis Tsu**, Director, HPV Vaccines Project, PATH, Associate Director, Reproductive Health, PATH; Affiliate Professor, Epidemiology, School of Public Health, University of Washington
- **Mr Yvan Deurbroeck**, Vice President International Public Relations & Communications, Medtronic Foundation
- **Ms Judith Watt**, Interim Director, NCD Alliance
- **Mr Hervé Hoppenot**, President, Novartis Oncology
- **Ms Silvana Luciani**, Advisor, Cancer Prevention and Control, Pan American Health Organization (PAHO)
- **Mr Chris Gray**, Senior Director, International Public Affairs, Pfizer *
- **Mr Martin Bernhardt**, Vice President of Relations with International Institutions, Sanofi Group *
- **Mr John McCarthy**, World Cancer Declaration Ambassador, Union for International Cancer Control (UICC)
- **Dr Julie Torode**, Deputy CEO and Advocacy and Programmes Director, UICC
- **Professor Martin Wiseman**, Medical and Scientific Advisor, World Cancer Research Fund International *
- **Dr Timothy Armstrong**, Coordinator, Surveillance and Population-based Prevention, Department of Chronic Diseases and Health Promotion, World Health Organization (WHO)
- **Dr Douglas Bettcher**, Director, Department of Tobacco Free Initiative, and Acting Director, Department of Chronic Diseases and Health Promotion, WHO
- **Dr Andreas Ullrich**, Medical Officer Cancer Control, Department Chronic Diseases and Health Promotion, WHO